Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24).

Caron A. Jacobson,Julio C. Chavez,Alison R. Sehgal,Basem M. William,Javier Munoz,Gilles Salles,Carla Casulo,Pashna N. Munshi,David G. Maloney,Sven de Vos,Ran Reshef,Lori A. Leslie,Ibrahim Yakoub-Agha,Olalekan O. Oluwole,Henry Chi Hang Fung,Vicki Plaks,Yin Yang,Jennifer Lee,Mauro P. Avanzi,Sattva S. Neelapu

Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24).

2021

7515Background: POD24 is an indicator of poor survival in iNHL (Casulo & Barr. Blood. 2019). In the ZUMA-5 Phase 2 study of axi-cel anti-CD19 CAR T-cell therapy in pts with R/R iNHL, overall respon...

Keywords:

Medicine
Internal medicine
anti cd20
Feature (computer vision)
in patient
Phases of clinical research
Oncology
Chemoimmunotherapy
Indolent Non-Hodgkin Lymphoma
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations